← Search & browse all drugs

rabies, inactivated, whole virus

J07BG01

Forms & Strengths

Suspension for injection: 2.5 international units (IU) per 0.5 mL or 1.0 mL vial/syringe

Adult Dosing

Pre-exposure prophylaxis: 1 mL intramuscularly (IM) on days 0, 7, and 21 or 28
Post-exposure prophylaxis (PEP) in non-immunized individuals: 1 mL IM on days 0, 3, 7, and 14, plus rabies immune globulin (RIG) on day 0
Post-exposure prophylaxis in previously immunized individuals: 1 mL IM on days 0 and 3 (no RIG)

Pediatric Dosing

Pre-exposure prophylaxis: 0.5 mL or 1 mL IM (depending on product) on days 0, 7, and 21 or 28
Post-exposure prophylaxis: Same schedule as adults (0.5 mL or 1 mL IM on days 0, 3, 7, and 14), plus weight-based RIG on day 0

Indications

Pre-exposure prophylaxis of rabies virus infection for individuals at high risk
Post-exposure prophylaxis following potential exposure to a rabid animal (e.g., bite, scratch, mucous membrane contact)

Mechanism of Action

Induces active immunity by stimulating the production of virus-neutralizing antibodies against rabies virus glycoproteins

Contraindications

Hypersensitivity to the active substance or any excipient (e.g., neomycin, streptomycin, polymyxin, beta-propiolactone)
Post-exposure prophylaxis has no absolute contraindications due to the 100% fatality rate of clinical rabies

Adverse Reactions

Injection site pain, erythema, swelling, and pruritus
Mild systemic effects: headache, nausea, abdominal pain, myalgia, dizziness, and low-grade fever
Rarely: immediate hypersensitivity or anaphylactoid reactions, serum sickness-like reactions

Drug Interactions

Immunosuppressive agents (corticosteroids, antineoplastics, radiation) may interfere with antibody response, potentially reducing vaccine efficacy
Do not mix rabies vaccine and rabies immune globulin (RIG) in the same syringe or administer in the same anatomical site

Curated Content: Needs Vetting Before Put to Clinical Use